Pharmacyte Biotech Inc (OTCMKTS:PMCB) fetched the attention of Goldman Small Cap Research which is a stock market research firm specializing on the microcap and small cap sectors. The firm said that it has released a new publication on Pharmacyte, a publicly-traded clinical stage biotech firm focused on formulation of treatments for diabetes and cancer. In the article, analyst Rob Goldman focuses on the impact of the current M&A activities and the Company’s standing.

The details

As per the article, the market is witnessing a flurry of biotech mergers and acquisitions and Pharmacyte Biotech is well-positioned in the industry. It can be better viewed as an unusually attractive potential acquisition target. After all, most of the major pharmaceutical firms are in panic mode. In the face of patent expirations of key products, they are looking to find suitable options. There is stiff competition from the big companies as well as from startups conducting mid-late stage clinical studies. To face the two-sided attack, the managements have become a part of the quasi-arms race to rapidly merge companies via acquisition that well-complements their existing therapeutic categories.

The technology

Goldman further mentioned that since Pharmacyte ‘Cell-in-a-Box’ live cell encapsulation technology possess broad potential applications, it could surface as a universal and unique therapy for the treatment of several forms of diabetes and diabetes and compete with numerous existing, billion dollar products. It translates the company into a prototypical acquisition target.

The scope

Most mid-stage and early stage firms such as Pharmacyte are keenly aware of big companies desire to acquire companies with unique technology. It represents a unique opportunity that can fetch those billions in revenue. As a result, clinical trials are designed for maximum safety and efficacy. They are also intended to fetch the attention of the biggest pharmaceutical players across world.

In last trading session, the stock price of Pharmacyte surged 2.32% to close at $0.154.

Previous articlePositiveID Corp (OTCMKTS:PSID) Detects Multiple Organisms From A Single Assay
Next articleCocrystal Pharma Inc (OTCBB:COCP) Trades In A Narrow Range
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.